Purchase this article with an account.
Kelly Fujikawa, Amar P Patel, Lawrence S Morse; Finasteride for Chronic Central Serous Chorioretinopathy. Invest. Ophthalmol. Vis. Sci. 2014;55(13):6382.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To investigate the efficacy of finasteride in the treatment of chronic central serous chorioretinopathy (CSCR).
A retrospective chart review was performed of seven eyes from six patients with chronic CSCR treated with finasteride 5mg daily. Patients treated with other therapies or taking exogenous steroids were excluded. Main outcome measures were best-corrected visual acuity (BCVA), central macular thickness (CMT), and subfoveal fluid height.
Mean age was 55.4 years (4 males, 2 females). Average BCVA was 0.221 (20/33) at baseline and 0.125 (20/27) at discontinuation of therapy (p=0.482). Average CMT was 337.1 um at baseline and 216.6 um at discontinuation of therapy (p=0.060). Average subfoveal fluid height was 114.6 um at baseline and 0 um at discontinuation of therapy (p=0.065). Average duration of therapy was 5.3 months with six of the seven eyes having complete resolution of subretinal fluid. Upon discontinuation of finasteride, three eyes had recurrence of subretinal fluid after an average duration of 4.7 months. No patient had any side effects from finasteride.
Finateride may be a useful treatment for CSCR. A larger study is needed to further evaluate the efficacy of finasteride for CSCR.
This PDF is available to Subscribers Only